Energy Transfer Partners, L.P. (NYSE:ETP) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -1.72% to 33.79 with around 4.96 Million shares have changed hands in this session. Energy Transfer Partners, L.P. (ETP) and Sunoco Logistics Partners L.P. (SXL), in their response to a statement from the Department of the Army, announced that the Administration’s decision not to issue an “easement” to Dakota Access Pipeline at this time is a purely political action.
The Administration stated that it has made a “policy decision”, which is Washington code for a political decision, the companies noted.”This is nothing new from this Administration, since over the last four months the Administration has demonstrated by its action and inaction that it intended to delay a decision in this matter until President Obama is out of office,” the companies said in their joined statement. The stock is going forward its fifty-two week low with 98.13% and lagging behind from its 52-week high price with -19.88%.
Similar, the positive performance for the quarter recorded as -15.06% and for the year was 13.44%, while the YTD performance remained at 13.65%. ETP has Average True Range for 14 days of 1.63.
Seattle Genetics, Inc. (NASDAQ:SGEN) [Trend Analysis] retains strong position in active trade, as shares scoring -0.66% to $66.26 in a active trade session, while looking at the shares volume, around 1.01 Million shares have changed hands in this session. Seattle Genetics presents Phase 1b data from VadastuximabTalirine; data showed remission rate of 76% (SGEN). The firm highlighted phase 1b data evaluating vadastuximabtalirine in combination with the frontline standard of care regimen for induction (cytarabine and daunorubicin, also known as 7+3) for younger patients with newly diagnosed acute myeloid leukemia.
Key findings include: Of 42 patients evaluable for response, 32 patients (76%) achieved a complete remission or complete remission with incomplete platelet or neutrophil recovery. Ninety-four% of the remissions occurred with one cycle of therapy.
Twenty-five of the 32 patients (78%) who achieved remission were negative for minimal residual disease (MRD). MRD-negative remission post-induction is generally correlated with reduced rates of relapse and improved overall survival.
Remissions were observed in higher-risk patients, including 18 of 21 (86%) and nine of 15 (60%) patients with intermediate or adverse cytogenetics, respectively. The firm has institutional ownership of 99.20%, while insider ownership included 1.10%. SGEN attains analyst recommendation of 2.40 with week’s performance of -1.09%. Investors looking further ahead will note that the Price to next year’s EPS is 11.50%.